Premium
Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population‐based cohort study in Taiwan
Author(s) -
Hsiao FeiYuan,
Tsai YiWen,
Wen YuWen,
Chen PeiFen,
Chou HaoYu,
Chen ChenHuan,
Kuo Ken N.,
Huang WengFoung
Publication year - 2010
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1999
Subject(s) - medicine , hazard ratio , retrospective cohort study , proportional hazards model , population , confidence interval , cohort study , heart failure , pharmacoepidemiology , cohort , adverse effect , environmental health , pharmacology , medical prescription
Background Thiazolidinediones (TZDs) are widely used antidiabetic agents, but there is great concern and conflicting reports over their possible effect on cardiovascular morbidity, especially in patients with heart failure (HF). Methods Using 2000–2005 Taiwan's National Health Insurance (NHI) claims data, this population‐based, retrospective cohort study investigated if there was an association between the cumulative TZD dose and clinical outcomes in type 2 diabetic patients recently hospitalized for HF. Study outcomes were death, first all‐cause readmission, and first readmission for HF. Cox proportional hazard models were used to analyze the association between TZD versus sulfonylurea (SU) use and these outcomes. Results Out of a total of 8139 eligible patients, 224 were taking TZD (65.63% female; mean [SD] age, 68.30[10.60] years) and 7915 were taking SU (55.10% female; 70.30[10.50] years). Patients taking TZD were at higher risk for readmission for HF (59 cases; HR 1.58 (95% confidence interval, 95%CI 1.44–1.72)), all‐cause readmission (147 cases; 1.40 (1.30–1.70)), and death (103 cases; 2.23 (1.58–3.14)). The higher the cumulative exposure to TZD, the greater the risk of HF readmission, all‐cause readmission, and death. Conclusion Among diabetic patients who had been hospitalized for HF, TZD users were at significantly greater risk for readmission for HF, all‐cause readmission, and death than SU users. The risk of all adverse clinical outcomes appeared to highly relate to cumulative exposure to TZD. These findings provide empirical evidence supporting the latest black box warnings issued by the United States Food and Drug Administration in August, 2007 advising that TZD not be prescribed for diabetic patients with symptomatic heart failure. Copyright © 2010 John Wiley & Sons, Ltd.